Intravitreal bevacizumab in refractory uveitic macular edema: One-year follow-up

European Journal of Ophthalmology

Volumn 19, Issue 4, 2009, Pages 622-629

  Cervantes Castañeda, Rene A ^a   Giuliari, Gian Paolo ^a,e   Gallagher, Michael J ^a   Yilmaz, Taygan ^a   MacDonell, Rebecca E ^b   Quinones, Karina ^a   Foster, Charles S ^a,c,d  

^a MASSACHUSETTS EYE RESEARCH AND SURGERY INSTITUTION   (United States)

^b DARTMOUTH INSTITUTE FOR HEALTH POLICY AND CLINICAL PRACTICE   (United States)

^c Massachusetts Eye Research and Surgery Institute   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

^e NONE   (United States)

Author keywords

Antivascular endothelium growth factor therapy; Bevacizumab; Ocular inflammation; Uveitic macular edema

Indexed keywords

BEVACIZUMAB; CARBONATE DEHYDRATASE INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; OCTREOTIDE; TRIAMCINOLONE ACETONIDE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; FEMALE; HUMAN; LONGITUDINAL STUDY; MALE; OPTICAL COHERENCE TOMOGRAPHY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; UVEA DISEASE; UVEITIC MACULA EDEMA; VISUAL ACUITY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; GLUCOCORTICOIDS; HUMANS; INJECTIONS; MACULAR EDEMA; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME; TRIAMCINOLONE ACETONIDE; UVEITIS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY; VITREOUS BODY; YOUNG ADULT;

EID: 70549089040     PISSN: 11206721     EISSN: None     Source Type: Journal    
DOI: 10.1177/112067210901900417     Document Type: Article

References (25)

1. Nussenblatt RB. The natural history of uveitis. Int Ophthalmol 1990; 14: 303-8.
2. Forrester JV. Uveitis: pathogenesis. Lancet 1991; 338: 1498-501.
3. Rothova A, Suttorp-van Schulten MS, Treffers WF, et al. Causes and frequency of blindness in patients with intraocular inflammatory disease. Br J Ophthalmol 1996; 80: 332-6.
4. Suttorp-Schulten MS, Rothova A. The possible impact of uveitis in blindness a literature survey. Br J Ophthalmol 1996; 80: 844-8.
5. Durrani OM, Tehrani NN, Marr JE, et al. Degree, duration, and causes of visual loss in uveitis. Br J Ophthalmol 2004; 88: 1159-62.
6. Bodaghi B, Cassoux N, Wechsler B, et al. Chronic severe uveitis: etiology and visual outcome in 927 patients from a single center. Medicine 2001; 80: 263-70.
7. Lardenoye CWTA, van Kooij B, Rothova A. Impact of macular edema on visual acuity in uveitis. Ophthalmology 2006; 113: 1446-9.
8. Nussenblatt RB, Kaufman SC, Palestine AG, et al. Macular thickening and visual acuity. Measurements in patients with cystoid macular edema. Ophthalmology 1987; 94: 1134-9.
9. Tran TH, de Smet MD, Bodaghi B. Uveitic macular oedema: correlation between optical coherence tomography patterns with visual acuity and fluorescein angiography. Br J Ophthalmol 2008; 92: 922-7.
10. Antcliff RJ, Stanford MR, Chauhan DS, et al. Comparison between optical coherence tomography and fundus fluorescein angiography for the detection of cystoid macular edema in patients with uveitis. Ophthalmology 2000; 107: 593-9.
11. Freeman G, Matos K, Pavesio CE. Cystoid macular oedema in uveitis: an unresolved problem. Eye 2001; 15: 12-7.
12. Rojas B, Zafirakis P, Christen W, et al. Medical treatment of macular edema in uveitis. Doc Ophthalmol 1999; 97: 399-407.
13. Bentley CR, Stanford MR, Shilling JS, et al. Macular ischemia in posterior uveitis. Eye 1993; 7: 411-4.
14. Rothova A. Medical treatment of cystoid macular edema. Ocul Immunol Inflamm 2002; 10: 239-46.
15. Kafkala C, Choi JY, Choopong P, et al. Octreotide as a treatment for uveitic cystoid macular edema. Arch Ophthalmol 2006; 124: 1353-5.
16. Cordero-Coma M, Sobrin L, Onal S, et al. Intravitreal bevacizumab for treatment of uveitic macular edema. Ophthalmology 2007; 114: 1574-9.
17. Mackensen F, Heinz C, Becker MD, et al. Intravitreal bevacizumab (Avastin) as a treatment for refractory macular edema in patients with uveitis: a pilot study. Retina 2008; 28: 41-5.
18. Nussenblatt RB, Palestine AG, Chan CC. Standardization of vitreal inflammatory activity in intermediate and posterior uveitis. Ophthalmology 1985; 92: 467-71.
19. Ben-Mahmud BM, Chan WH, Abdulahad RM, et al. Clinical validation of a link between TNF-alpha and the glycosylation enzyme core 2 GlcNc-T and the relationship of this link to diabetic retinopathy. Diabetologia 2006; 49: 2185-91.
20. Nakano T, Ohara O Teraoka H, et al. Glucocorticoids suppress group II phospholipase A2 production by blocking mRNA synthesis and post-transcriptional expression. J Biol Chem 1990; 265: 12745-8.
21. Salaria S, Chana G, Caldara F, et al. Microarray analysis of cultured human brain aggregates following cortisol exposure: implications for cellular functions relevant to mood disorders. Neurobiol Dis 2006; 23: 630-6.
22. Aiello LP. Vascular endothelial growth factor and the eye: biochemical mechanisms of action and implications for novel therapies. Ophthalmic Res 1997; 29: 354-62.
23. Fine H, Baffi J, Reed GF, et al. Aqueous humor and plasma vascular endothelial growth factor in uveitis associated cystoid macular edema. Am J Ophthalmol 2001; 132: 794-6.
24. Brasil OF, Smith SD, Galor A, et al. Predictive factors for short-term visual outcome after intravitreal triamcinolone acetonide injection for diabetic macular oedema: an optical coherence tomography study. Br J Ophthalmol 2007; 91: 761-5.
25. Markomichelakis NN, Halkiadakis I, Pantelia E, et al. Pattern of macular edema in patients with uveitis: qualitative and quantitative assessment using optical coherence tomography. Ophthalmology 2004; 111: 946-53.